Inventor · disambiguated record
Sebastian Amigorena
Also filed as: AMIGORENA SEBASTIAN · AMIGORENA SEBASTIAN DIEGO
11 granted patents·25 pending applications·230 citations·filing 1999–2025
89Inventor score
Files withINST CURIE20MNEMO THERAPEUTICS5INST NAT SANTE RECH MED4THERAVECTYS2BIOMUNEX PHARMACEUTICALS1
Top patents by PatentIndex Score
36 records- 0193US6899863B1Method for preparing membrane vesiclesINST NAT SANTE RECH MED·Filed 2000·Granted May 31, 2005·161 cites·15 claims
- 0287US11285176B2Immune cells defective for Suv39h1INST CURIE·Filed 2021·Granted Mar 29, 2022·1 cites·13 claims
- 0386US12371471B2Immune cells defective for SUV39H1INST CURIE·Filed 2024·Granted Jul 29, 2025·0 cites·16 claims
- 0484US10752668B2Lentiviral vectors for regulated expression of a chimeric antigen receptor moleculeTHERAVECTYS·Filed 2015·Granted Aug 25, 2020·8 cites·5 claims
- 0582US10576103B2Immune cells defective for SUV39H1INST CURIE·Filed 2019·Granted Mar 3, 2020·3 cites·18 claims
- 0680US11622978B2Immune cells defective for SUV39H1INST CURIE·Filed 2020·Granted Apr 11, 2023·1 cites·23 claims
- 0778US2023201264A1Immune cells defective for suv39h1INST CURIE·Filed 2023·Application pending·0 cites
- 0877US7625573B2Sensitization process for antigen-presenting cells and means for implementing the processCENTRE NAT RECH SCIENT·Filed 2003·Granted Dec 1, 2009·12 cites·12 claims
- 0977US6685911B1Sensitization process for antigen-presenting cells and means for implementing the processINST NAT SANTE RECH MED·Filed 1999·Granted Feb 3, 2004·43 cites·5 claims
- 1077US2024216388A1Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapyINST CURIE·Filed 2024·Application pending·0 cites
- 1175US2022331332A1Methods and pharmaceutical compositions for the treatment of th2 mediated diseasesINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 1268US2025388906A1Immune cells defective for suv39h1MNEMO THERAPEUTICS·Filed 2025·Application pending·0 cites
- 1367US9827216B2Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumorSCHIFFRIN EDUARDO·Filed 2009·Granted Nov 28, 2017·1 cites·10 claims
- 1466US2025213616A1Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious diseaseMNEMO THERAPEUTICS·Filed 2023·Application pending·0 cites
- 1564US2025115916A1Modulation of suv39h1 expression by rnasMNEMO THERAPEUTICS·Filed 2023·Application pending·0 cites
- 1663US12152077B1Immunotherapy targeting tumor neoantigenic peptidesINST CURIE·Filed 2023·Granted Nov 26, 2024·0 cites·9 claims
- 1762US2025304915A1Myeloid Cells Overexpressing BCL2INST CURIE·Filed 2022·Application pending·0 cites
- 1861US2025302930A1Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastomaINST CURIE·Filed 2023·Application pending·0 cites
- 1960US2020157225A1Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapyINST CURIE·Filed 2020·Application pending·0 cites
- 2060US2020147099A1Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapyINST CURIE·Filed 2018·Application pending·0 cites
- 2159US2022251572A1Immune cells defective for suv39h1MNEMO THERAPEUTICS·Filed 2020·Application pending·0 cites
- 2252US2004241179A1Compositions and methods using lactadherin or variants thereofFiled 2004·Application pending·0 cites
- 2351US2015038496A1Methods and pharmaceutical compositions for the treatment of th2 mediated diseasesINST NAT SANTE RECH MED·Filed 2012·Application pending·0 cites
- 2450US2021009653A1Lentiviral vectors for regulated expression of a chimeric antigen receptor moleculeTHERAVECTYS·Filed 2020·Application pending·0 cites
- 2548US2019117664A1Methods and pharmaceutical compositions for the treatment of th2 mediated diseasesINSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICAL INSERM·Filed 2018·Application pending·0 cites
- 2647US2023303974A1Immune Cells Defective for SOCS1INST CURIE·Filed 2021·Application pending·0 cites
- 2746US10968281B2Anti-LSP1 antibodyINST CURIE·Filed 2017·Granted Apr 6, 2021·0 cites·22 claims
- 2846US2022193198A1Interleukin-2 Variants with Modified Biological ActivityINST CURIE·Filed 2020·Application pending·0 cites
- 2946US2024082372A1Immunotherapy targeting tumor neoantigenic peptidesINST CURIE·Filed 2020·Application pending·0 cites
- 3046US2025041412A1Transmembrane neoantigenic peptidesINST CURIE·Filed 2022·Application pending·0 cites
- 3146US2025302929A1Tumor neoantigenic peptidesINST CURIE·Filed 2022·Application pending·0 cites
- 3245US2023322952A1Multispecific antibodies that bind both mait and tumor cellsBIOMUNEX PHARMACEUTICALS·Filed 2021·Application pending·0 cites
- 3342US2010278818A1Antibody specific for the Tn antigen for the treatment of cancerINST CURIE·Filed 2008·Application pending·0 cites
- 3441US2025352577A1Tumor neoantigenic peptides and uses thereofMNEMO THERAPEUTICS·Filed 2022·Application pending·0 cites
- 3540US2021060158A1Agonist of aryl hydrocarbon receptor for use in cancer combination therapyINST CURIE·Filed 2018·Application pending·0 cites
- 3638US2020405853A1Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapyINST CURIE·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sebastian Amigorena files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →